According to a recent LinkedIn post from Formlabs, the company’s 3D printing technology is being used in the production of the PSYONIC Ability Hand, which is described as one of the fastest bionic hands on the market. The post highlights that the device is manufactured using the Form 4 printer and high-performance resins from Formlabs, emphasizing performance and accessibility in prosthetics.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Formlabs’ hardware and materials are gaining traction in high-value, specialized medical applications, where reliability and customization are critical. For investors, this points to potential growth in healthcare and prosthetics demand for Formlabs’ additive manufacturing solutions, which could support higher-margin, application-specific revenue streams and reinforce its position in the professional 3D printing segment.
By aligning its technology with a human-impact narrative and a cutting-edge bionic product, Formlabs appears to be underscoring the real-world use cases of its ecosystem rather than general-purpose printing. This focus may help differentiate the company from lower-cost, commoditized 3D printing providers and could strengthen its brand among clinical, research, and medtech customers seeking validated use cases.
If such partnerships and deployments expand, Formlabs could deepen its integration into the medical device development workflow, potentially driving recurring revenue from materials as well as from hardware placements. However, the post does not disclose financial terms, adoption scale, or regulatory details, so the magnitude and timing of any financial impact remain unclear and would depend on broader market uptake of devices like the Ability Hand.